Tríona Ní Chonghaile
Index: 10.1126/scitranslmed.aat3887
Full Text: HTML
Combining BCL-2 inhibitor venetoclax with monoclonal CD20 antibody rituximab greatly enhances progression-free survival compared with bendamustine-rituximab in a phase 3 trial of relapsed or refractory chronic lymphocytic leukemia patients.